Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10,709 GBX | -0.31% | +2.67% | +1.00% |
01:19pm | ASTRAZENECA : Deutsche Bank reiterates its Sell rating | ZD |
Mar. 27 | AstraZeneca CEO Sees No Impact from Biosecure Act | MT |
Financials (USD)
Sales 2024 * | 51.01B | Sales 2025 * | 54.61B | Capitalization | 210B |
---|---|---|---|---|---|
Net income 2024 * | 8.97B | Net income 2025 * | 10.25B | EV / Sales 2024 * | 4.47 x |
Net Debt 2024 * | 17.99B | Net Debt 2025 * | 11.5B | EV / Sales 2025 * | 4.06 x |
P/E ratio 2024 * |
23.8
x | P/E ratio 2025 * |
20.8
x | Employees | 89,900 |
Yield 2024 * |
2.29% | Yield 2025 * |
2.4% | Free-Float | 96.49% |
Latest transcript on AstraZeneca PLC
1 day | -0.34% | ||
1 week | +2.69% | ||
Current month | +7.26% | ||
1 month | +5.19% | ||
3 months | +1.27% | ||
6 months | -2.71% | ||
Current year | +1.02% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.20% | 11 M€ | +0.83% | - | |
5.39% | 196 M€ | +12.16% | ||
5.17% | 18 M€ | +7.01% | - | |
4.89% | 770 M€ | +6.83% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 10,706 | -0.34% | 262 569 |
24-03-27 | 10,742 | +2.89% | 2,607,662 |
24-03-26 | 10,440 | +0.44% | 1,745,894 |
24-03-25 | 10,394 | -0.84% | 1,557,854 |
24-03-22 | 10,482 | +0.52% | 1,243,839 |
Delayed Quote London S.E., March 28, 2024 at 08:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.02% | 210B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.75% | 210B | |
-6.65% | 201B | |
-3.51% | 157B | |
-0.60% | 153B |